Overview / Abstract: |
The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy. This is the second of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In each 0.5-hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of a case study with text, faculty and patient videos, and evidence-based animated slides with narration. The activity is interactive, and the learner can advance through the material at their desired pace. |
Expiration |
Feb 19, 2022 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
Format |
Online |
Credits / Hours |
0.5 |
Accreditation |
ACCME, ANCC, ACPE |
Presenters / Authors / Faculty |
Neera Dahl, MD, PhD |
Activity Specialities / Related Topics |
Primary Care, Pharmacology, Nephrology |
Sponsors / Supporters / Grant Providers |
Otsuka America Pharmaceutical, Inc. |
Keywords / Search Terms |
CMEology, nephrologists, nephrology nurse practitioners, ADPKD, Physician, nurse, physician assistant, nephrology Free CE CME, primary care, primary care physicians |